Redwire Inks SpaceX Deal for Orbital Pharma Lab, Shares Jump 10%
RDW has more than doubled off its 52-week low of $4.87.
Summary
Redwire announced a partnership with SpaceX to send its Pharmaceutical In-Space Laboratory (PIL) devices to low-Earth orbit aboard a Starfall spacecraft, with the first mission targeted for 2028. The deal adds a high-profile commercial space partner and opens a new revenue avenue in orbital drug manufacturing. This follows yesterday's Q2 report showing a 90% revenue surge to $117.1M and a narrowed loss, which already drove a 14% rally. Today's 9.7% gain reflects incremental enthusiasm for the SpaceX tie-up and the reaffirmed $450M-$500M full-year revenue outlook. With a record $542.1M backlog and a strengthened balance sheet, Redwire is scaling to meet defense and space demand, though the 2028 timeline tempers near-term revenue impact.
At the time of this announcement, RDW was trading at $11.70 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $4.87 to $26.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.